Hemostemix Inc. (CVE:HEM – Get Free Report) reached a new 52-week high during trading on Wednesday . The company traded as high as C$0.10 and last traded at C$0.09, with a volume of 1500 shares trading hands. The stock had previously closed at C$0.09.
Hemostemix Price Performance
The business’s 50 day simple moving average is C$0.08 and its 200 day simple moving average is C$0.06. The company has a market capitalization of C$7.84 million, a price-to-earnings ratio of -4.50 and a beta of 0.20.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Featured Stories
- Five stocks we like better than Hemostemix
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- What a Trump Win Looks Like for the Market Now and Into 2025
- Dividend Payout Ratio Calculator
- Russell 2000 Surge Post-Election: How to Play the Small-Cap Pop
- Investing in Commodities: What Are They? How to Invest in Them
- Macro Headwinds Send Microchip Technology Stock to the Buy Zone
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png?v=20211130090720&h=45&w=95&zc=2){kind=logo}
